Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F Schatzberg

Showing results (11-20 of 256) with videos related to

Pageof 26
Sort By:
The Journal of Clinical Psychiatry|October 14, 2003
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorderAlan F Schatzberg
The American Journal of Psychiatry|May 2, 2019
Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major DepressionAlan F Schatzberg
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|June 17, 2014
Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depressionAlan F Schatzberg
The American Journal of Psychiatry|October 5, 2010
Presidential addressAlan F Schatzberg
The Journal of Clinical Psychiatry|July 31, 2007
Safety and tolerability of antidepressants: weighing the impact on treatment decisionsAlan F Schatzberg
The American Journal of Psychiatry|May 2, 2020
Some Comments on Psychedelic ResearchAlan F Schatzberg
The Journal of Clinical Psychiatry|November 24, 2004
Employing pharmacologic treatment of bipolar disorder to greatest effectAlan F Schatzberg
The American Journal of Psychiatry|December 2, 2021
Mechanisms of Action of Ketamine and EsketamineAlan F Schatzberg
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|March 19, 2009
The silver lining of recent effectiveness trialsAlan F Schatzberg
CNS Spectrums|March 26, 2009
Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disordersAlan F Schatzberg
Pageof 26

Showing results (11-20 of 256) with videos related to

Sort By:
Pageof 26
The Journal of Clinical Psychiatry|October 14, 2003
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorderAlan F Schatzberg
The American Journal of Psychiatry|May 2, 2019
Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major DepressionAlan F Schatzberg
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|June 17, 2014
Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depressionAlan F Schatzberg
The American Journal of Psychiatry|October 5, 2010
Presidential addressAlan F Schatzberg
The Journal of Clinical Psychiatry|July 31, 2007
Safety and tolerability of antidepressants: weighing the impact on treatment decisionsAlan F Schatzberg
The American Journal of Psychiatry|May 2, 2020
Some Comments on Psychedelic ResearchAlan F Schatzberg
The Journal of Clinical Psychiatry|November 24, 2004
Employing pharmacologic treatment of bipolar disorder to greatest effectAlan F Schatzberg
The American Journal of Psychiatry|December 2, 2021
Mechanisms of Action of Ketamine and EsketamineAlan F Schatzberg
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|March 19, 2009
The silver lining of recent effectiveness trialsAlan F Schatzberg
CNS Spectrums|March 26, 2009
Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disordersAlan F Schatzberg
Pageof 26